109 related articles for article (PubMed ID: 23484395)
1. [Evaluation of antibody response to HPV vaccination in HIV infected girls].
Ołdakowska A; Marczyńska M; Dobosz S; Stańska-Perka A; Popielska J; Szczepańska-Putz M
Przegl Epidemiol; 2012; 66(4):651-5. PubMed ID: 23484395
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
3. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ
Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
[TBL] [Abstract][Full Text] [Related]
9. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study.
Höpfl R; Petter A; Thaler P; Sarcletti M; Widschwendter A; Zangerle R
BMC Infect Dis; 2003 Apr; 3():6. PubMed ID: 12723991
[TBL] [Abstract][Full Text] [Related]
11. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis B vaccination effectiveness based on anti-HBs antibodies presence in children vertically infected with HIV].
Ołdakowska A; Marczyńska M
Przegl Epidemiol; 2010; 64(2):323-8. PubMed ID: 20731246
[TBL] [Abstract][Full Text] [Related]
13. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
14. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
Mahoney MC
J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
[TBL] [Abstract][Full Text] [Related]
15. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
17. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
Bonanni P; Boccalini S; Bechini A
Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
[TBL] [Abstract][Full Text] [Related]
20. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
